DUBLIN, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been accepted for oral and poster presentations at the AACR Annual Meeting, which will take place April 12-16 in San Diego, California.
An oral presentation by Dr. Steven Warner will highlight SuperGen's PIM
Kinase Inhibitor in cell lines from hematological and solid malignancies.
The poster presentations will focus on data concerning many of SuperGen's
current oncology programs, including the lead clinical compound, MP-470,
and its ability to suppress the repair of double stranded DNA breaks
following treatment with DNA-damaging agents.
SuperGen's schedule of presentations is as follows:
Date Time (PDT) Abstract # and Title
Sunday, 8 a.m. - 12 p.m. #671 -- Inhibition of erlotinib resistance
April 13 on HER-family tyrosine kinases by
combination with MP-470, a
multi-targeted TK inhibitor in prostate and
Monday, 1 p.m. - 5 p.m. #2613 -- The dinucleotide prodrug of
April 14 decitabine demonstrated increased in vivo
efficacy due to enhanced drug delivery and
Tuesday, 8 a.m. - noon #4083 -- MP-470, a potent oral Rad51
April 15 suppressor is safe and tolerable in
Tuesday, 2:25 p.m. - #4974 -- A potent small molecule PIM kinase
April 15 2:40 p.m. inhibitor with activity in cell lines from
(oral presentation) hematological and solid malignancies
Tuesday, 1 p.m. - 5 p.m. #4891 -- Activity of the multi-targeted,
April 15 receptor tyrosine kinase inhibitor MP-470
against synovial sarcoma cells
Wednesday, 8 a.m. - noon #5729 -- Pharmacokinetics of MP-529, a
April 16 selective Aurora A kinase inhibitor, in a
novel subcutaneous delivery system
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of 1995. These
statements are typically preceded by words such as "believes," "expects,"
"anticipates," "intends," "will," "may," "should," or similar expressions.
These forward-looking statements are not guarantees of future performance
and involve a number of risks and uncertainties that may cause actual
results to differ materially from the results discussed in these
statements. Factors that might cause the company's results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to, the ability to discover,
develop and move target compounds into clinical development and other risks
and uncertainties detailed from time to time in the company's filings with
the Securities and Exchange Commission including its most recently filed
Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of
these forward-looking statements to conform them to actual results.
Timothy L. Enns Mary M. Vegh
SuperGen, Inc. SuperGen, Inc.
SVP, Corporate Communications Manager, Investor Relations
& Business Development
Tel: (925) 560-0100 Tel: (925) 560-2845
|SOURCE SuperGen Inc.|
Copyright©2008 PR Newswire.
All rights reserved